Syndax Pharmaceuticals (SNDX) Debt to Equity (2015 - 2024)

Syndax Pharmaceuticals' Debt to Equity history runs 5 years deep, the most recent figure standing at $1.19 for Q4 2024.

• In Q4 2024, Debt to Equity changed N/A year-over-year to $1.19; the TTM figure through Dec 2024 stood at $1.19 (changed N/A YoY), while the FY2024 annual figure was $1.19, changed N/A from the prior year.
• Debt to Equity was $1.19 for Q4 2024 at Syndax Pharmaceuticals, up from $0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.19 in Q4 2024 to a low of $0.05 in Q4 2021.
• Historically, Debt to Equity has averaged $0.22 across 4 years, with a median of $0.09 in 2021.
• Biggest YoY gain for Debt to Equity was 29.61% in 2021; the steepest drop was 76.03% in 2021.
• A 4-year view of Debt to Equity shows it stood at $0.08 in 2020, then sank by 38.36% to $0.05 in 2021, then advanced by 13.52% to $0.06 in 2022, then surged by 2036.64% to $1.19 in 2024.
• The last three Debt to Equity figures came in at $1.19 (Q4 2024), $0.06 (Q2 2022), and $0.05 (Q1 2022), per Business Quant data.